MX2021011876A - Formulaciones liposomicas y metodos de uso y preparacion de las mismas. - Google Patents

Formulaciones liposomicas y metodos de uso y preparacion de las mismas.

Info

Publication number
MX2021011876A
MX2021011876A MX2021011876A MX2021011876A MX2021011876A MX 2021011876 A MX2021011876 A MX 2021011876A MX 2021011876 A MX2021011876 A MX 2021011876A MX 2021011876 A MX2021011876 A MX 2021011876A MX 2021011876 A MX2021011876 A MX 2021011876A
Authority
MX
Mexico
Prior art keywords
preparing
methods
compositions
phosphorylated
liposomal formulations
Prior art date
Application number
MX2021011876A
Other languages
English (en)
Inventor
Agnes Rafalko
Teppei Shirakura
Samuel Eric Greenberg
Original Assignee
Glycomine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomine Inc filed Critical Glycomine Inc
Publication of MX2021011876A publication Critical patent/MX2021011876A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La descripción proporciona terapias de reemplazo de carbohidratos fosforilados (CRT) que incluyen composiciones de carbohidratos fosforilados y fosfolípidos, así como métodos para preparar tales composiciones. Tales composiciones son adecuadas para la administración farmacéutica de carbohidratos fosforilados al interior de la célula, retículo endoplásmico y aparato de Golgi, y se pueden utilizar para el tratamiento contra enfermedades de CDG tipo I y tipo II, así como otros trastornos metabólicos.
MX2021011876A 2019-03-29 2020-03-27 Formulaciones liposomicas y metodos de uso y preparacion de las mismas. MX2021011876A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962826874P 2019-03-29 2019-03-29
PCT/US2020/025246 WO2020205530A1 (en) 2019-03-29 2020-03-27 Liposomal formulations, and methods of using and preparing thereof

Publications (1)

Publication Number Publication Date
MX2021011876A true MX2021011876A (es) 2022-01-04

Family

ID=72666933

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011876A MX2021011876A (es) 2019-03-29 2020-03-27 Formulaciones liposomicas y metodos de uso y preparacion de las mismas.

Country Status (18)

Country Link
US (1) US20220184107A1 (es)
EP (1) EP3946365A4 (es)
JP (1) JP2022527638A (es)
KR (1) KR20210143906A (es)
CN (1) CN113873998A (es)
AR (1) AR119705A1 (es)
AU (1) AU2020252005A1 (es)
BR (1) BR112021019593A2 (es)
CA (1) CA3134828A1 (es)
CL (1) CL2021002512A1 (es)
CO (1) CO2021014274A2 (es)
EA (1) EA202192663A1 (es)
IL (1) IL286713A (es)
MX (1) MX2021011876A (es)
PE (1) PE20212366A1 (es)
SG (1) SG11202110623PA (es)
TW (1) TW202102231A (es)
WO (1) WO2020205530A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023205628A1 (en) * 2022-04-18 2023-10-26 City Of Hope Lipid nanoparticles, nucleic acids, and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010112301A (ko) * 1999-03-02 2001-12-20 질레스피 카롤 리포좀내에 생활성 복합체의 포집
US7060291B1 (en) * 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
CA2442261A1 (en) * 2001-03-26 2002-10-03 Alza Corporation Liposome composition for improved intracellular delivery of a therapeutic agent
US20090191259A1 (en) * 2002-01-09 2009-07-30 Transave, Inc. Efficient liposomal encapsulation
CA2472462A1 (en) * 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient nucleic acid encapsulation into medium sized liposomes
CA2761916A1 (fr) * 2009-05-14 2010-11-18 Sanofi Pasteur Procede pour adjuver le lipopolysaccharide (lps) des bacteries a gram-negatif
DK3046537T3 (da) * 2013-09-16 2021-10-11 Glycomine Inc Farmaceutisk fremstilling af kulhydrater til terapeutisk anvendelse
US20170165374A1 (en) * 2015-11-18 2017-06-15 Insmed, Inc. Compositions and methods for treating bacterial infections

Also Published As

Publication number Publication date
CN113873998A (zh) 2021-12-31
US20220184107A1 (en) 2022-06-16
AR119705A1 (es) 2022-01-05
CA3134828A1 (en) 2020-10-08
SG11202110623PA (en) 2021-10-28
KR20210143906A (ko) 2021-11-29
CL2021002512A1 (es) 2023-01-06
AU2020252005A1 (en) 2021-11-04
PE20212366A1 (es) 2021-12-21
WO2020205530A1 (en) 2020-10-08
EP3946365A1 (en) 2022-02-09
EA202192663A1 (ru) 2022-03-01
CO2021014274A2 (es) 2022-01-17
BR112021019593A2 (pt) 2021-12-14
EP3946365A4 (en) 2023-04-19
IL286713A (en) 2021-10-31
JP2022527638A (ja) 2022-06-02
TW202102231A (zh) 2021-01-16

Similar Documents

Publication Publication Date Title
AU2017265937A1 (en) Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
CR20200196A (es) Proteínas trispecìficas y mètodos de uso
WO2018144093A3 (en) ENHANCED SKIN CARE FORMULATIONS
MX2020003413A (es) Preparacion y almacenamiento de formulaciones liposomales de arn adecuadas para terapia.
EP4036079A3 (en) Compounds and compositions for intracellular delivery of agents
EP4286012A3 (en) Compounds and compositions for intracellular delivery of therapeutic agents
WO2016140878A3 (en) Prodrugs riluzole and their method of use
PH12020550341A1 (en) Niraparib formulations
MX2022016463A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2021001884A (es) Compuestos de pirazina y usos de los mismos.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
CR20190433A (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
BR112014024964A2 (pt) formulação compósita compreendendo comprimido esferoidal de multi-unidade (must) encapsulado em cápsula dura e método para sua preparação
CY1125361T1 (el) Φαρμακευτικο παρασκευασμα υδατανθρακων για θεραπευτικη χρηση
MX2021015311A (es) Formulas parenterales de lisofosfatidilcolina tales como lpc-dha, lpc-epa y sus usos en terapia.
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
BR112019017393A8 (pt) Composição farmacêutica de evolocumab e seu uso, kit, método para preparar polipeptídeo de ligação a pcsk9 e método para formular polipeptídeo terapêutico
WO2018170150A3 (en) Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins
MX2021012138A (es) Preparacion y almacenamiento de formulaciones de arn liposomico adecuadas para terapia.
MX2021011876A (es) Formulaciones liposomicas y metodos de uso y preparacion de las mismas.
MX2016009217A (es) Inmunoterapia basada en liposomas.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2021011596A (es) Compuestos y composiciones como moduladores de se?alizacion tlr.
MX339746B (es) Vitamina d3 y análogos de la misma para aliviar efectos secundarios asociados con la quimioterapia.